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Abstract 
Influenza can be a serious disease and constitutes a threat to the population. Every year, seasonal influenza 
epidemics affect about 5-15% of the world’s population. Some frail categories (such as the elderly) can 
develop complications, request hospitalization, and may die. In order to reduce the medical, social and 
economic burden of influenza, vaccination is recommended by many health authorities worldwide. 
Italy has a national programme of influenza vaccination which targets specific categories, such as subjects 
with chronic conditions, pregnant women, healthcare workers and those over 65 years old. Despite this 
opportunity for prevention, however, vaccination coverage in Italy does not reach the minimum recommended 
threshold of 75%. 
This paper reports some interventions that can improve coverage rates of the elderly, such as “tailor-made” 
information campaigns, healthcare workers training and the adoption of innovative communication strategies 
in order to implement vaccination strategies that take into account the needs of the elderly population, the 
involvement of elderly people’s associations in awareness-raising activities and strengthening the role of 
general practitioners in promoting influenza vaccination.
Background
Every year, seasonal influenza has a 
significant epidemiological, clinical and 
economic impact (1-3,). According to recent 
World Health Organization (WHO) estimates, 
about 5-15% of the world’s population is 
affected by influenza-like illness (ILI) each 
year, resulting in 3-5 million serious cases 
and 250,000-500,000 deaths (4). Annual 
epidemics are associated with high morbidity 
and mortality worldwide. In Europe, the 
European Centre for Disease Prevention 
and Control (ECDC) estimates that, on the 
average, every year 40,000 subjects die 
prematurely as a result of influenza infection; 
90% of these deaths occur among subjects 
over 65 years of age, especially those with 
chronic underlying diseases (5).
Owing to the high burden of influenza, 
the WHO’s Global Influenza Surveillance 
and Response System monitors virus 
evolution, updates seasonal influenza 
vaccine composition, and serves as an 
alert mechanism for influenza viruses with 
pandemic potential (6).
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In Italy, INFLUNET, the national 
influenza surveillance system, records from 
5 to 8 million cases of ILI per year (7). The 
data from the last 10 influenza seasons (2007 
- 2017) reveal that the highest incidence of 
illness occurs in young children (0-4 years), 
while the age-class with the greatest risk of 
complications, hospitalization and death is 
that of the elderly (7).
Other influenza surveillance systems are 
active in Italy, such as monitoring access 
to the Emergency Departments (ED) and 
syndromic surveillance. However, these 
systems do not cover the entire country. Since 
the pandemic season (2009/10), a dedicated 
surveillance system run by 11 Italian 
Regions has monitored the trend in serious 
and complicated cases of influenza. In the 
2016/2017 season, 219 serious cases were 
registered and 53 people died. The median 
age of patients with severe disease was 72 
years (range 0-94). In 95% of serious cases 
and 100% of fatal cases, the patients had at 
least one underlying chronic disease, the 
most common being cardiovascular disease 
(74%), followed by chronic respiratory 
disorders (63%), diabetes (45%) and 
obesity (31%). In most severe cases, A/
H3N2 virus (63%) was detected, followed 
by A /H1N1pdm09 virus (6%) and B virus 
(4%). In 69% of fatal cases, A/H3N2 virus 
was isolated, while A/H1N1pdm09 virus 
was isolated in 10% (8). Mortality varies 
from year to year, depending on vaccine 
effectiveness, the intensity of the influenza 
epidemic, the virulence of the circulating 
virus and the pre-existing immunity level 
of the population.
Decisions concerning immunization 
programmes should take into account many 
aspects: disease burden, vaccine-specific 
issues such as vaccine performance and safety, 
programme impact, programmatic issues, 
logistical questions, and political will.
Here, we present several potential 
strategies that could be implemented in order 
to increase coverage rates in elderly.
Influenza Prevention
Routine annual vaccination is the most 
effective means of avoiding influenza illness, 
reducing the associated complications 
and, consequently, reducing the impact of 
epidemics (9-11).
The WHO recommends seasonal influenza 
vaccination for those people who are most 
at risk of developing serious complications; 
priority groups for vaccination include: 
the elderly, subjects with certain chronic 
diseases, pregnant women, healthcare 
workers and children aged 6-59 months 
(12).
Increasing seasonal influenza vaccination 
coverage among these groups is fundamental 
for reducing the burden of influenza in the 
European Union (EU). WHO/Europe also 
monitors seasonal influenza vaccination 
coverage and policies in the EU in order to 
provide technical assistance for EU Member 
States that are expanding their seasonal 
influenza vaccination programmes (13).
In Italy, vaccination is offered free of 
charge to specific categories, such as subjects 
with chronic conditions, pregnant women, 
healthcare workers and subjects over 65 
years of age (14).
The Italian National Health System, in 
collaboration with the Regional Authorities, 
usually launches influenza immunization 
programmes in late October, as the best 
time to vaccinate is between October and 
December, before influenza begins to spread 
in the community (14).
Influenza vaccines of the elderly
Currently, in Italy, four types of flu 
vaccines are used for the seasonal vaccination 
campaign: trivalent inactivated vaccines 
split or subunit (TIVs), trivalent inactivated 
vaccine adjuvanted with MF59® (aTIV) 
and quadrivalent split vaccines (QIV) (14). 
National and international studies have 
demonstrated the public health benefits of 
vaccination, particularly when the vaccine 
18 D. Amicizia et al.
strains match with circulating strains (15-
20).
Some examples of studies aimed at 
investigating the effectiveness of vaccination 
in the elderly are reported below.
Gross et al. (21) reported that TIVs were 
effective against a variety of influenza-
related outcomes. In 20 studies examined, 
56% effectiveness (95% CI: 39-68%) was 
demonstrated in preventing any respiratory 
illness, 53% (95% CI: 35-66%) in preventing 
pneumonia, 48% (95% CI: 28-65%) in 
preventing hospitalizations and 68% (95% 
CI: 56-76%) regarding the outcome of 
all-cause mortality. Respect to Gross et 
al., a meta-analysis of effectiveness of 
influenza vaccine in persons aged 65 years, 
performed by Vu et al. (22) reported lower 
values. Influenza vaccination has been 
shown to be effective in reducing ILI [35% 
(95% CI: 19-47%)], ILI hospitalization 
and influenza [33% (95% CI: 27-38%)], 
mortality following hospitalization for ILI 
and pneumonia [47% (95% CI: 25-62%)] 
and all-cause mortality [50% (95% CI: 45-
56%)].
MF59-adjuvanted seasonal influenza 
vaccine was the first vaccine specifically 
designed to overcome the phenomenon of 
immunosenescence and to improve vaccine 
efficacy in the elderly (23). A very recent 
systematic review and meta-analysis (24), 
conducted on the effectiveness of MF59-
adjuvanted seasonal influenza vaccine in the 
elderly, showed an adjusted effectiveness 
of aTIV of 51% (95% CI: 39-61%) in 
preventing hospitalizations for pneumonia/
influenza among community-dwelling 
seniors. Pooled results of the adjusted 
vaccine effectiveness against laboratory-
confirmed influenza were also high (60.1%). 
Other single community-based studies have 
reported very high effectiveness of aTIV 
in preventing hospitalizations for acute 
coronary [87% (95% CI: 35-97%)] and 
cerebrovascular [93% (95% CI: 52-99%)] 
events (24). aTIV proved highly effective 
[94% (95% CI: 47-100%] in reducing ILI 
among institutionalized elderly subjects. 
Furthermore, aTIV displayed greater 
efficacy than non-adjuvanted vaccines 
in preventing hospitalizations due to 
pneumonia/influenza [adjusted risk ratio 
0.75 (95% CI: 0.57-0.98)] and laboratory-
confirmed influenza [adjusted odds ratio 
0.37 (0.14-0.96)] (24).
As quadrivalent vaccines have been 
recently licensed, no effectiveness studies 
performed in the elderly have been published 
so far.
As TIVs are used from long time, the 
administration of millions of doses did not 
highlight safety problems (25, 26). A good 
safety profile was also demonstrated for 
aTIV (27) and QIV (28).
Influenza vaccine coverage
Although vaccination can effectively 
prevent influenza illness, vaccination 
coverage in Italy does not reach the minimum 
recommended threshold of 75% (Figure 1). 
Indeed, a downward trend of coverage in 
the elderly has been observed since the 
pandemic season of 2009-2010, and the 
average national coverage rate has fell from 
65.6% in 2009-2010 to 49% in 2014-2015 
(minimum value); a slight upward trend was 
observed in the 2016-2017 season, when 
coverage reached 52.6% (Figure 1).
This unsatisfactory level of coverage 
results in an excessive recourse to Emergency 
Departments (EDs) and in an increase in 
hospital admissions for complications in 
the elderly during epidemic peaks, causing 
organizational strain and increasing direct 
health costs (29-33).
In order to improve vaccination coverage, 
it is necessary to plan and implement 
vaccination promotion strategies by adopting 
new methodological approaches. These 
should take into account the fact that the goals 
of the vaccination campaign are to reduce 
the number of individuals at risk of illness, 
hospitalization and death, and to alleviate 
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the social costs associated with morbidity 
and mortality. These goals can be reached by 
expanding access to immunization services 
and extending vaccination campaigns to 
other target populations, such as subjects 50-
65 years of age and children, on the basis of 
the most recent scientific evidence available 
(12). Moreover, an electronic database 
dedicated to influenza vaccination coverage 
in each Italian region should be created as 
soon as possible.
Which strategies can be implemented 
in order to increase coverage rates in 
the elderly?
The perceived low effectiveness of 
influenza vaccines and the fear of possible 
adverse events are the main obstacles to 
increasing vaccination coverage.
Measuring influenza immunization 
coverage every year is important in order 
to evaluate immunization programmes, 
to identify sub-populations with low 
immunization coverage and to monitor 
p rogress  towards  I ta l ian  na t iona l 
immunization coverage goals. Collecting this 
information helps in planning immunization 
programmes for subsequent seasons.
In order to improve vaccination 
coverage in subjects aged > 65 years, 
several interventions have been identified: 
(i) “tailor-made” information campaigns, 
( i i )  heal th worker  t raining on the 
epidemiological, clinical and economic 
impact of influenza and on the adoption of 
innovative communication strategies for the 
implementation of vaccination strategies, 
that take into account the needs of the 
elderly population; (iii) involving elderly 
people’s associations in awareness-raising 
activities; (iv) strengthening the role of 
general practitioners in promoting influenza 
vaccine; (v) raising awareness among 
general practitioners that they can contribute 
to the creation of regional lists on the basis 
of disease exemption codes, in order to 
create patient databases and directly alert 
patients to vaccination campaign (strategy 
Figure 1 - Influenza vaccination in Italy: vaccine coverage (%) in elderly from 2000-01 to 2016-17 seasons.
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mainly targeted to the elderly with chronic 
conditions). These interventions were also 
indicated by the Ministry of Health for the 
2017-2018 season (14). For individuals who 
are unable to get to a vaccination centre, 
home assistance coordinated by specialists 
can allow the vaccine to be administered 
directly at the patient’s home or at residential 
institutions for long-term care facilities. 
Moreover, vaccination can be undertaken 
at the end of inpatient and outpatient visits. 
The international scientific literature has 
already described the benefits of vaccinating 
(elderly) patients during hospitalization, 
underlining that this strategy significantly 
increases the percentage of coverage in the 
subgroups at greatest risk (34, 35).
It should be noted that general practitioners 
have a fundamental role to play in promoting 
influenza vaccination among those involved 
in the care of elderly patients, including 
caregivers (family members, healthcare 
workers, volunteers, etc.). Indeed, it is well 
known that vaccinating subjects who are 
not directly at risk, but who are in frequent 
contact with elderly people enhances 
community immunity, thereby reducing the 
spread of the virus. (14, 36).
Conclusions
Influenza is a significant illness in 
terms of severity and complications. The 
treatment of influenza and its complications 
consumes considerable resources, which 
could otherwise be used for other essential 
healthcare services. In Italy, it has been 
estimated that the global costs attributable to 
influenza between 1999 and 2008 amounted 
to around €15 billion, about €1.5 billion for 
each influenza season (3).
Vaccination is an undoubtedly efficacious 
means of preventing influenza. It is well-
recognized that, compared with non-
vaccination, annual influenza immunization 
is cost-effective or even cost-saving in 
different setting and population groups, 
including the elderly (37). A very recent 
cost-effectiveness analysis of different 
seasonal influenza vaccines in the elderly 
Italian population showed that aTIV had 
the most favourable economic profile and 
should be considered as a preferential choice 
for Italian subjects aged 65 years or above 
(38).
Finally, as the population ages, the 
demand for health resources is destined to 
increase. Therefore, in order to maximise 
the benefits of vaccination, it is necessary 
to plan and systematically implement 
influenza vaccination in target populations 
(the elderly) and to extend it to other age-
groups (children aged 6-59 months of age 
and subjects 50-65 years).
Riassunto
Vaccinazione antinfluenzale negli anziani: tempo 
di rilancio
L’influenza può essere una malattia severa e costituisce 
una minaccia per la popolazione. Ogni anno, le epidemie 
influenzali stagionali colpiscono circa il 5-15% della 
popolazione mondiale. Alcune categorie fragili (come gli 
anziani) possono sviluppare complicanze, richiedere il 
ricovero in ospedale e possono andare incontro a morte. 
Al fine di ridurre il burden sanitario, sociale ed econo-
mico dell’influenza, la vaccinazione è raccomandata da 
molte autorità sanitarie in tutto il mondo.
L’Italia ha un programma nazionale di vaccinazione 
contro l’influenza che si rivolge a categorie specifiche, 
come i soggetti con condizioni croniche, le donne incinte, 
gli operatori sanitari e coloro che hanno più di 65 anni. 
Nonostante questa opportunità di prevenzione, la coper-
tura vaccinale in Italia non raggiunge la soglia minima 
raccomandata del 75%.
Questo lavoro riporta alcuni interventi che possono mi-
gliorare i tassi di copertura della vaccinazione influenzale 
negli anziani, come ad esempio le campagne di informa-
zione “su misura”, la formazione degli operatori sanitari 
e l’adozione di strategie di comunicazione innovative 
al fine di implementare strategie di vaccinazione che 
tengano conto delle esigenze della popolazione anziana, 
il coinvolgimento delle associazioni degli anziani nelle 
attività di sensibilizzazione e il rafforzamento del ruolo 
dei medici di medicina generale nella promozione della 
vaccinazione antinfluenzale.
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